Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

Research Watch

Nuclear FAK Promotes Immune Evasion in Squamous Cell Carcinoma

DOI: 10.1158/2159-8290.CD-RW2015-189 Published December 2015
  • Article
  • Figures & Data
  • Info & Metrics
Loading
  • Major finding: Nuclear FAK stimulates cytokine transcription and Treg recruitment, promoting tumor immune evasion.

  • Mechanism: CCL5 induction by nuclear FAK promotes tumor growth by inducing Tregs and inhibiting CD8+ T cells.

  • Impact: FAK inhibitors in clinical development may cause immune-mediated squamous cell carcinoma regression.

Figure1

Focal adhesion kinase (FAK) is a tyrosine kinase involved in focal adhesions, migration, invasion, survival, and proliferation, and is required for tumorigenesis in multiple tumor types. FAK contains putative nuclear localizations signals, and can translocate to the nucleus under conditions of cellular stress. However, the role of nuclear FAK has not been well defined. Serrels, Lund, and colleagues showed that, in a syngeneic mouse model of squamous cell carcinoma (SCC), FAK-deficient cells exhibited an initial growth period followed by complete tumor regression in immunocompetent mice, whereas in immunodeficient mice, FAK deletion had only a small effect on growth. The tumor regression in FAK-deficient mice required CD8+ T cells; in contrast, infiltrating CD8+ T cells in FAK wild-type tumors were characterized by increased expression of markers of T-cell exhaustion and were associated with increased numbers of regulatory T cells (Treg), suggesting that FAK promotes the formation of an immunosuppressive microenvironment that promotes tumor growth. Mechanistically, nuclear FAK regulated Tregs via its association with transcriptional regulators on chromatin, leading to upregulation of chemokines and cytokines, including Tgfb2 and chemokine (C-C motif) ligand 5 (Ccl5), which has a known role in the recruitment and expansion of Tregs. The effects of nuclear FAK in promoting SCC tumorigenesis required its catalytic activity, as expression of a catalytically inactive FAK mutant or inhibition of FAK with a small-molecule inhibitor (VS-4718) led to SCC tumor regression. Consistent with these findings, VS-4718 reduced the number of Tregs, and its antitumor activity was dependent on CD8+ T cells. Together, these results indicate that nuclear FAK promotes immune evasion in SCC by generating an immunosuppressive microenvironment, and provide a rationale for further study of FAK kinase inhibitors including VS-4718, which is already in early clinical development.

Serrels A, Lund T, Serrels B, Byron A, McPherson RC, von Kriegsheim A, et al. Nuclear FAK controls chemokine transcription, Tregs, and evasion of anti-tumor immunity. Cell 2015;163:160–73.

  • ©2015 American Association for Cancer Research.
PreviousNext
Back to top
Cancer Discovery: 5 (12)
December 2015
Volume 5, Issue 12
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Nuclear FAK Promotes Immune Evasion in Squamous Cell Carcinoma
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Nuclear FAK Promotes Immune Evasion in Squamous Cell Carcinoma
Cancer Discov December 1 2015 (5) (12) OF15; DOI: 10.1158/2159-8290.CD-RW2015-189

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Nuclear FAK Promotes Immune Evasion in Squamous Cell Carcinoma
Cancer Discov December 1 2015 (5) (12) OF15; DOI: 10.1158/2159-8290.CD-RW2015-189
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
  • Figures & Data
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Research Watch

  • Structures Identify Selpercatinib and Pralsetinib Resistance Mechanisms
  • Cryo-EM Structures Reveal Mechanism of Anticancer MCT1 Inhibitors
  • Computational Tool Characterizes Previously Unidentified Tumor Subtypes
Show more Research Watch

Immune Evasion

  • The m6A-Binding Protein YTHDF1 Mediates Immune Evasion
  • Chronic Inflammation Promotes CSN5-Mediated PD-L1 Stabilization
  • Structural Variations Disrupting the PD-L1 3′-UTR Enable Immune Evasion
Show more Immune Evasion
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement